Document Detail

New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy.
MedLine Citation:
PMID:  23135865     Owner:  NLM     Status:  Publisher    
Incretin-based therapy was first made available for the treatment of type 2 diabetes mellitus (T2DM) in the US in 2006 and in Japan in 2009. Four DPP-4 inhibitors and two GLP-1 analog/receptor agonists are currently available. The effects of incretin-based therapy are assumed to be exerted mainly through the hormonal and neuronal actions of one of the incretins, GLP-1, which is secreted from L cells localized in the small intestine. The benefits of this therapy over conventional sulfonylureas or insulin injections, such as fewer hypoglycemic events and reduced body weight gain, derive from the glucose-dependent insulinotropic effect. The protective effects of this therapy on vulnerable pancreatic β-cells and against micro/macroangiopathy in T2DM are also most welcome. Indications and/or contraindications for incretin-based therapy should be clarified by prospectively studying the experiences of Japanese T2DM patients undergoing this therapy in the clinical setting.
Mitsuyoshi Namba; Tomoyuki Katsuno; Yoshiki Kusunoki; Toshihiro Matsuo; Masayuki Miuchi; Jun-Ichiro Miyagawa
Related Documents :
24138325 - An evidence-based shared decision making programme on the prevention of myocardial infa...
23010555 - Sleep disturbances and low psychological well-being are associated with an increased ri...
23182405 - Predictors of postprandial blood glucose response to biphasic insulin analogue therapy.
24254975 - Potential implications of the choice among three alternative treatment targets for apol...
15945405 - Blood glucose awareness training helps return insulin-treated aviators to the cockpit.
17697055 - The role of angiotensin ii type 1 receptor blockers in the prevention and management of...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-8
Journal Detail:
Title:  Clinical and experimental nephrology     Volume:  -     ISSN:  1437-7799     ISO Abbreviation:  Clin. Exp. Nephrol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9709923     Medline TA:  Clin Exp Nephrol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  KIM-1 expression predicts renal outcomes in IgA nephropathy.
Next Document:  Clinical features and long-term renal outcomes of Japanese patients with obesity-related glomerulopa...